Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors

Background. Anti-PD1/PDL1 immune checkpoint inhibitors (ICIs) showed promising results in breast cancer, and exploration of additional actionable immune checkpoints is ongoing. Inflammatory breast cancer (IBC) is an aggressive form of disease, the immune tumor microenvironment (TME) of which is poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertucci, François, Boudin, Laurys, Finetti, Pascal, Van Berckelaer, Christophe, Van Dam, Peter, Dirix, Luc, Viens, Patrice, Gonçalves, Anthony, Ueno, Naoto T., Van Laere, Steven, Birnbaum, Daniel, Mamessier, Emilie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158040/
https://www.ncbi.nlm.nih.gov/pubmed/34104544
http://dx.doi.org/10.1080/2162402X.2021.1929724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158040/
https://www.ncbi.nlm.nih.gov/pubmed/34104544
http://dx.doi.org/10.1080/2162402X.2021.1929724

Ejemplares similares